Fig. 8: Patients with stroke and MI show increased circulating NETs and reduced IgA levels that can be treated with DNase-I. | Nature Cardiovascular Research

Fig. 8: Patients with stroke and MI show increased circulating NETs and reduced IgA levels that can be treated with DNase-I.

From: Stroke and myocardial infarction induce neutrophil extracellular trap release disrupting lymphoid organ structure and immunoglobulin secretion

Fig. 8

a,b, Relative plasma levels of citH3−DNA (a) and NE−DNA complexes (b) in patients with stroke and healthy individuals (n = 14−23 per group, ****P < 0.0001). c, A significant negative correlation between plasma citH3-DNA complex levels and IgA amounts in patients with stroke. d,e, Relative plasma levels of citH3-DNA (d) and NE-DNA complexes in patients with MI and healthy controls (n = 17−38 per group, ****P < 0.0001). f, A significant negative correlation between plasma citH3-DNA complex levels and IgA amounts in MI (n = 17−38 per group). g,h, citH3-DNA (n = 7−8 per group, *P = 0.0263) (g) or NE−DNA (n = 7−9 per group, **P = 0.0012) (h) complexes at 24 h after therapy in the plasma of patients with stroke treated at timepoint 0 with tPA alone or combined with recombinant human DNase-I. i, Levels of plasma IgA in the same patients with stroke (n = 7−8 per group, **P = 0.0093). The IgA data were normalized to the baseline plasma IgA levels of the same individuals before the administration of treatment, and percentage values are presented. Data represent mean ± s.d., Mann−Whitney U-test. HC, healthy control; MI, myocardial infarction.

Back to article page